Trial
NCT03845049
Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Centre Hospitalier Universitaire Dijon
Collaborators
—
Condition
Macular Telangiectasia
Intervention
Inclusion examinations
Why stopped
very rare disease, many difficulties in recruiting patients, inclusion rate far too slow, making it impossible to meet the main objective within a reasonable timeframe. the sponsor therefore decided to stop the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-26